Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Curr Microbiol ; 59(4): 374-9, 2009 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19629593

RESUMEN

Current drugs for treating leishmaniasis are still associated with significant toxicity and failure rates. Thus, new effective and less toxic antileishmanial agents are still in need. Herein, we tested a series of sulfonamide 4-methoxychalcone derivatives against L. amazonensis promastigote and amastigote forms to identify its antileishmanial profile against this species compared to L. braziliensis. In addition, we used molecular modeling tools to determine stereoelectronic features that may lead to the antileishmanial profile. Interestingly, all tested compounds were able to affect L. amazonensis promastigote form in a concentration-dependent manner and with low cytotoxicity, except for derivative 3g. However, our results showed that compound 3f (para-Cl) presents the best profile against both L. amazonensis forms (promastigote and amastigote), differently from that observed for L. braziliensis, when compound 3i was the most active. Structure-activity relationship (SAR) analysis of these derivatives pointed molecular volume, HOMO density, and conformational aspects as important characteristics for parasitic profile. Overall, sulfonamide 4-methoxychalcone derivatives may be pointed out not only as lead compounds for treating leishmaniasis (i.e., 3f) but also as experimental tools presenting parasite-selectivity (i.e., 3i).


Asunto(s)
Chalconas/farmacología , Inhibidores de Crecimiento/farmacología , Leishmania mexicana/efectos de los fármacos , Leishmania mexicana/crecimiento & desarrollo , Sulfonamidas/farmacología , Animales , Chalconas/química , Chalconas/toxicidad , Relación Dosis-Respuesta a Droga , Inhibidores de Crecimiento/química , Concentración 50 Inhibidora , Leishmania braziliensis/efectos de los fármacos , Leishmania braziliensis/crecimiento & desarrollo , Estructura Molecular , Relación Estructura-Actividad , Sulfonamidas/química , Sulfonamidas/toxicidad
2.
J Biomed Nanotechnol ; 7(3): 406-14, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21830481

RESUMEN

Curcumin is a polyphenol obtained from the plant Curcuma longa (called turmeric) that displays several pharmacological activities, including anti-inflammatory, antioxidant, antimicrobial and antitumoral activity, but clinical use has been limited by its poor solubility in water and, consequently, minimal systemic bioavailability. We have therefore formulated the drug into nanocarrier systems in an attempt to improve its therapeutic properties. This study evaluates the effect of intraperitoneally administered nanocapsules containing curcumin on subcutaneous melanoma in mice inoculated with B16-F10 cells, and on the cytotoxicity activity against B16-F10 cells in vitro. Phagocytic uptake of formulations was also evaluated upon incubation with macrophage J774 cells by fluorescence microscopy. Lipid and polymeric nanocapsules were prepared by the phase inversion and nanoprecipitation methods, respectively. The uptake of the lipid nanocapsules prepared using Solutol HS15 was significantly reduced in J774 cells. Curcumin, as free drug or as drug-loaded nanocapsules, was administrated at a dose of 6 mg/kg twice a week for 21 days. Free drug and curcumin-loaded nanocapsules significantly reduced tumor volume (P < 0.05 vs. control), but no difference was found in the antitumor activity displayed by lipid and polymeric nanocapsules. This assumption was supported by the in vitro study, in which free curcumin as well as loaded into nanocapsules caused significant reduction of cell viability in a concentration- and time-dependent manner.


Asunto(s)
Curcumina/farmacología , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Nanocápsulas , Tensoactivos , Animales , Transporte Biológico/efectos de los fármacos , Línea Celular Tumoral , Curcumina/farmacocinética , Curcumina/uso terapéutico , Estabilidad de Medicamentos , Iones , Liposomas , Macrófagos/inmunología , Melanoma Experimental/tratamiento farmacológico , Ratones , Ratones Endogámicos C57BL , Nanocápsulas/química , Tamaño de la Partícula , Tensoactivos/química
3.
Eur J Med Chem ; 44(2): 755-63, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18554753

RESUMEN

Despite clinical importance of leishmaniasis, an infectious disease that affects 12 thousand million people in 88 countries, the treatment is still unsatisfactory due to its limited efficacy, cost expensive and undesirable side effects. Aiming to develop new antileishmanial lead compounds, we used a rational approach to synthesize a new set of sulfonamide 4-methoxychalcone derivatives (3a-3i) and evaluate the sulfonamide and methoxy moieties as promising adding-groups to chalcones. For that purpose we tested this new set against Leishmania braziliensis promastigotes and intracellular amastigotes and determined its cell toxicity profile. Interestingly all compounds presented a concentration-dependent antileishmanial profile and the benzylamino derivative (3i) showed a biological activity better than pentamidine. None of these compounds affected Trypanosoma cruzi epimastigotes, which suggests a specific antileishmanial profile. The structure-activity analysis of these sulfonamide 4-methoxychalcone derivatives pointed the molecular volume, the HOMO density concentrated in the chalcone moiety and the conformational structure of the compounds as important structural and stereoelectronic features for the antileishmanial activity. In addition, these compounds also fulfilled Lipinski rule of 5 and presented druglikeness similar to antileishmanial drugs. Altogether these results point the sulfonamide 4-methoxychalcone derivatives as potential lead compounds for designing new candidates for leishmaniasis treatment.


Asunto(s)
Antiprotozoarios/síntesis química , Sulfonamidas/síntesis química , Animales , Antiprotozoarios/farmacología , Chalcona/análogos & derivados , Relación Dosis-Respuesta a Droga , Leishmania braziliensis/efectos de los fármacos , Modelos Moleculares , Pruebas de Sensibilidad Parasitaria , Relación Estructura-Actividad , Sulfonamidas/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA